Growing Hair Without Chemicals: How Niostem Turned a Cancer Lab Discovery Into a Wearable

Most of us treat hair loss like a fact of life. You either accept it, or you throw a bottle of chemicals at your scalp and hope for the best. Sometimes it works, sometimes it doesn't. But what if the answer wasn't a bottle at all? What if it was a wearable device that could quietly wake your hair follicles back up?

That's exactly what Dr. Chacón-Martínez set out to build. He's a cell biologist who spent more than 15 years studying stem cells, including five years as a post-doctoral researcher at the world-famous Max Planck Institute in Germany. He didn't just publish papers on it. He filed a patent for a technology that let him grow skin cancer in a petri dish and study it in ways nobody could before.

Then he did something most scientists never do. He walked away from a stable research position to bet everything on a hunch: that you could regrow hair without any drug at all. Seven years later, that hunch is a real company called Niostem, with two peer-reviewed clinical trials, cloud-connected devices in the field, and a money-back guarantee bold enough to make most founders sweat.

In this conversation, Dr. Chacón-Martínez walks us through the whole thing. Why the drug path is a billion-euro trap. How electrical pulses can "keep your hair in the gym." What it actually feels like to switch off your scientist brain and learn to pitch investors. And why some problems are better left unsolved until they actually show up. Honestly, it's one of the most refreshing science-to-startup stories we've had on the show.

Key Takeaways: From Petri Dish to Product

The Science Behind the Device:

• Niostem uses low-level electrical stimulation on the scalp to reactivate the hair growth pathway, no drugs, no hormones, no piercing the skin.
• The analogy is a muscle: stop exercising it and it shrinks. Hair follicles that miniaturize with pattern baldness can be "kept in the gym" and prevented from shrinking further.
• In a published pilot of 21 people, all of them stopped their hair loss and roughly 96% showed signs of regrowth.

The Business Reality Check:

• Developing a single drug can cost 1 to 1.5 billion euros and take 10 to 20 years. A device that achieves the same biological goal sidesteps almost all of that.
• Niostem raised 1.5 million euros on Indiegogo in 2023 for a product that didn't exist yet, they had to invent even how it looked.
• Money-back requests run under 1% of purchases, and devices returned broken sit under 2%. Cloud data shows who actually used the device six-plus times a week.

Founder Wisdom:

• Scientists sell with data. Business people buy the bigger picture. Learning to switch between the two, without being fake, is a slow grind.
• Don't build systems for problems that haven't arrived. Solve them when they show up.
• No reward without the work. Perseverance beats waiting, every single time.

Q: You spent years as a researcher. When did you realize your research could actually become a product?

Dr. Chacón-Martínez: I've been studying cell biology and stem cells for many years, probably more than 10 to 15 years. My interest was actually cancer, and there are some types of cancer that sprawl from stem cells, so I started studying skin cancer. Normally you'd study this in mice, which is slow, so I started thinking, how can I make tools that speed this up so it doesn't take me 10 years to get interesting findings? I developed a new technology, and there's a patent for that from my time at Max Planck, that let you take this cancer in a petri dish and actually play with it. And to do that I had to work with the normal hair stem cells, the cell type that grows hair. Fast forward, and I discovered you could use that same tool to find new treatments for hair loss and skin regeneration.

🔥 ChaiNet's Hot Take: The best products aren't planned, they're stumbled into sideways. He went looking for cancer answers and walked out holding a cure for baldness.

Q: So how did you go from "I found something" to actually building a device?

Dr. Chacón-Martínez: My initial thought was, okay, if I can discover new treatments, a treatment is normally a drug, a small molecule you take or inject or put on your scalp. But the drug discovery path is super long and costs hundreds of millions of euros. So when I left my post-doc position at Max Planck after five years, I was convinced this could help a lot of people. I tried the pharma route, and it didn't even work out. Then I joined a program called Entrepreneur First in Berlin, and I met my co-founder, an electronic engineer. When I told him I had a tool to help people, he asked, why do we have to use drugs? Maybe we can use devices. And that clicked, because part of my research was understanding how our body responds to things that aren't drugs, like pressure, poking, stretching. That's how we landed on building a device instead of a chemical.

🔥 ChaiNet's Hot Take: Sometimes your co-founder's job is to ask the dumb question that reframes everything. "Why a drug?" was worth a billion euros.

Q: What does the device actually do to regrow hair?

Dr. Chacón-Martínez: It transmits to the scalp, only the upper layer, and applies a small current, low-level electrical stimulation. That activates the regeneration program. It's completely non-invasive, you just put it on and make sure it contacts the scalp, because if you touch it lightly the hair sits in between. Once it's on, it stimulates the growth pathway of the hair. When you've lost hair because of genetically inherited pattern baldness, which is called androgenetic alopecia, you can actually start reversing the process with this physical stimulation. And we have data. We published a trial testing it against a control group using a placebo device, a fake one that looks identical but doesn't stimulate. We published that just last week, and it shows you don't need any hormonal repressor or chemicals.

🔥 ChaiNet's Hot Take: A placebo helmet that looks exactly like the real one. That's not marketing confidence, that's a company that actually wanted to know if it works.

Q: Can you explain what's happening to the follicles in simple terms?

Dr. Chacón-Martínez: Imagine your follicles are the plant pot that hosts the plant, and the hair is the plant. With pattern baldness, those pots are shrinking over time. As the condition progresses, or just with aging, the pot gets smaller, so the hair gets thinner and thinner until it seems like you have no hair, but actually you do, it's just very minute. With the electrical stimulation, we tell the body not to start this shrinking process and to keep the organ active, because hair follicles are organs. I make a parallel with a muscle. You work it out and it grows. Stop exercising it and it degenerates, loses mass, gets weak. Same with hair. So we basically keep the hair in the gym, and by doing that we prevent it from miniaturizing.

🔥 ChaiNet's Hot Take: "Keep the hair in the gym" is the cleanest explanation of follicle science you'll ever hear. Your scalp has a fitness routine now.

Q: Was it a culture shock going from research to startup life?

Dr. Chacón-Martínez: I don't think it was a shock, because I was always interested in innovation. That's partly why I went to Max Planck, they do cutting-edge science. But one thing is being in a lab discovering things, and a totally different role is being the person who takes that knowledge and brings it to the public. When I started the company with my co-founder Sam, the first thing I had to do was go back to the lab, because we had a good hypothesis that electrical stimulation could activate hair regeneration but no data. So I did my lab work and got the factual proof. The real learning came later. Talking science to peers was easy, but talking to business people was different. They don't care about the details. They care about how you'll scale, how you'll raise money, who else can participate.

🔥 ChaiNet's Hot Take: Scientists earn trust with data. Founders earn it with a story. The hardest part of the transition is learning to do both without lying to either room.

Q: Your website offers a money-back guarantee on a nearly 1,000-euro product. Where does that confidence come from?

Dr. Chacón-Martínez: We made that decision when we launched. I founded the company seven years ago, and before that we spent about three years going from idea to proof of concept. In 2023 we came to market on Indiegogo and raised 1.5 million euros for a product that didn't exist. Then we ran a small clinical pilot with 21 people, also published in peer-reviewed journals. All of them stopped their hair loss, and about 96% had signs of regrowth. We knew 20 people is a small sample, so we bet it might work in 80% instead of 100%. But even if 20% asked for their money back, what we gain in trust and credibility is more than what we could lose. Our devices are cloud-connected, so if someone says it didn't work, I can check the dashboard and see they didn't actually use it. After three years, our money-back rate is under 1%.

🔥 ChaiNet's Hot Take: A guarantee backed by usage data isn't a gamble, it's a filter. You can't blame the device if the dashboard says it sat in a drawer.

Q: Hardware is brutal. How did you deal with that reality?

Dr. Chacón-Martínez: You're absolutely right, the hardware business has a lot of obstacles. It's expensive and slow, and that's why it took us so long to reach market. But once we were there, we tested the device in that 21-person pilot and knew it worked. The build quality turned out to be really good. The electronics are solid, the battery lasts, you can charge it and use it for at least 30 days, even a month and a half, without recharging. We have devices in the field for about two years now, and the number that come back broken is less than 2%. Of course, if you drop it from the fifth floor it'll smash, but that's the same as any phone or laptop, that's on you, not the manufacturer.

🔥 ChaiNet's Hot Take: Five years to ship one device sounds insane until you realize the alternative was 20 years and a billion euros. Slow hardware still beats slower pharma.

Q: Which sales channels have surprised you, and which have worked best?

Dr. Chacón-Martínez: We rely on our own e-commerce site for about 95% of sales. We recently launched on Amazon, especially in the DACH region, Germany, Austria, Switzerland, and we're available across European Amazon too. But people prefer to buy on our website. Part of that is we haven't invested as much in Amazon marketing yet. The bigger reason is our product needs an educational step before you buy it. Until yesterday the price was 990 euros for a one-time hardware purchase with the app. In Germany you compare that to a new iPhone or Google Pixel. But when you buy a phone you know exactly what you get. When you buy a Niostem, the device looks futuristic, some people call it a helmet, and you don't know if it'll work for you. That's a hard 1,000-euro decision.

🔥 ChaiNet's Hot Take: People pay 1,000 euros for a phone without blinking because they know what it does. Selling the unknown means you sell the education first and the hardware second.

Q: You just launched a subscription model. Why the shift?

Dr. Chacón-Martínez: Today, actually, we launched it. Instead of paying 1,000 euros at once, you pay 89 euros a month with a minimum retention of six months. Why six? Because our clinical data shows results by six months. By three months there are results, but they're not all visible yet. It's not really a subscription like Spotify or iTunes, it's more of a try-before-you-buy. If you pay for 14 months, you own the device forever. It reduces the investment massively, almost 90%. If you start and decide it's not working for you, because it doesn't work for everybody, that's normal, even aspirin doesn't work for everybody, you just send it back and stop paying.

🔥 ChaiNet's Hot Take: Turning a scary 1,000-euro leap into an 89-euro monthly nod is the whole game. Lower the entry barrier and let the results do the closing.

Q: Aren't you worried about devices coming back damaged, or people gaming the system?

Dr. Chacón-Martínez: We had concerns about fraud and mistreatment, since the devices technically belong to us, we just lease them. But we've had units in the field for about two years and less than 2% come back broken. Something I've learned on the founder journey is that you solve problems when they come, not before. Build solutions when they arrive, don't build systems for things that might happen. A good example: at first we thought we needed to block one user to one device, so you couldn't share it with a friend. But my team pushed back and asked, why limit how people share something they own? If I have a car, I lend it to my wife or my kids. So we changed it. Some customers share the device with a spouse who also has hair loss, different accounts, same device. So few people do it that we don't worry.

🔥 ChaiNet's Hot Take: The best operators triage problems like an ER, not a to-do list. Not everything bleeding today needs stitches today.

Q: Everyone's talking about AI. Does it play a role in Niostem?

Dr. Chacón-Martínez: I'm super interested in the topic generally, but our product isn't heavily focused on AI, and won't be in the near future. Right now we're optimizing the user experience rather than making hardcore changes to the hardware, because we know we have a solid product. What we've been building for over a year is a system that tells you how much hair you have, because when you're trying to grow hair, the most important thing is data. Most customers, 99% of them, won't go to a dermatologist and get a tattoo marker to measure precisely. They just want to be told if it works. So we're developing sensors that detect how much hair you have and automatically adjust the stimulation. And we've trained machine learning models on thousands of longitudinal photos, the same person at one, two, three, six months, even a year, so an algorithm can estimate hair on your phone. We also use AI for the back office, especially translations, since we're a German company with no native German speaker on the team.

🔥 ChaiNet's Hot Take: The smartest AI move here isn't the device, it's measuring progress people can actually see. When the results are invisible, the data becomes the product.

Q: What's the best piece of advice you'd give a founder?

Dr. Chacón-Martínez: I heard this even from my grandma, my dad, my mom. You need to work hard and you need to persevere if you want to achieve your goals. Even outside entrepreneurship, if you know what you want, even if it's a dream, there's no way to get there by sitting and waiting or not working 120%. Every time you fail, if you're convinced that's what you want, you stand up and carry on. As a founder there are 99 bad things that happen even every week, and maybe only one good one. But if you believe in the goal and you get people, the team, to believe you can do it together, it's a matter of time and hard work. No reward without work. There's no free lunch. Sometimes you just learn, and learning is super important.

🔥 ChaiNet's Hot Take: Ninety-nine bad things a week, one good one. Founders don't win because the odds are good, they win because they keep showing up when the odds aren't.

Final Thoughts: Betting on Biology, One Pulse at a Time

Dr. Chacón-Martínez's core belief: "There is no reward without actual work. It's the same as when people say there is no free lunch. Working hard pays off, and sometimes you just learn."

The bottom line: What makes the Niostem story so compelling isn't just the science, though the science is genuinely wild. It's the decision to reject the obvious path. The obvious move for a stem cell researcher with a promising discovery is the drug pipeline: a billion euros, two decades, and big pharma holding all the cards. Dr. Chacón-Martínez looked at that and asked whether the same biological outcome could be reached with a physical device instead of a chemical. That single reframe turned an impossible timeline into a shippable product.

For anyone building at the intersection of deep science and real-world impact, the lessons stack up fast. Data earns you credibility, but a story earns you customers. A bold guarantee is only bold if you can't back it up, and cloud data made theirs bulletproof. Reducing the barrier to entry from 990 euros to 89 a month isn't a discount, it's a completely different psychology of buying. And maybe the most underrated one: don't drown in hypothetical problems. Solve fraud, sharing, and breakage when they actually show up, not in a spreadsheet at 2 a.m.

Where this goes next is fascinating. As the sensor and machine learning work matures, Niostem is quietly building the one thing every hair-loss customer secretly craves, proof they can see on their own phone. If they nail that feedback loop, they won't just be selling a device that works. They'll be selling the confidence to keep using it. And in a category built on decades of false promises, confidence might be the rarest ingredient of all.

Q: How can people connect with you and learn more about Niostem?

Dr. Chacón-Martínez: The best place to start is our website, where we've put a lot of effort into educating people, including both of our peer-reviewed clinical trials and the research we've run with independent contract research organizations. It's real scientific proof, not just marketing material. If you're curious about the science or the device, that's where you'll find everything, and with the new subscription model you can try it for 89 euros a month rather than committing all at once. I'm always happy to talk with people who are genuinely interested in the technology.

Final words: The story of Niostem is really a story about refusing to accept the default. Hair loss was "just something you accept." Deep science meant "you need a billion euros and 20 years." Dr. Chacón-Martínez looked at both of those givens and quietly asked, what if that's not true? The takeaway for the rest of us isn't about hair at all. It's that the biggest opportunities usually hide inside the assumptions everybody stopped questioning. Find the "obvious" thing nobody challenges, challenge it, and be ready to stand up and carry on 99 times before it works.

---